Citations

Showing 10 of 108135 citations.

Machine learning approach to differentiation of peripheral schwannomas and neurofibromas: A multi-center study
Zhang, Michael , Tong, Elizabeth , Wong, Sam, Hamrick, Forrest , Mohammadzadeh, Maryam , Rao, Vaishnavi , Pendleton, Courtney , Hug, Nicholas F. , Biswal, Sandip , Seekins, Jayne , Napel, Sandy , Spinner, Robert J. , Yeom, Kristen W. , Wilson, Thomas J. , Wilson, Thomas J , Rao, Vaishnavi L , Smith, Brandon W. , Mahan, Mark A

Mayo Clinic

Neuro-Oncology | September 6, 2021 | Volume: 24 | Issue: 4 | Pages: 601-609

10.1093/neuonc/noab211 | PMID 34487172 Get It

Abstract Background Non-invasive differentiation between schwannomas and neurofibromas is important for appropriate management, preoperative counseling, and surgical planning, but has proven difficult using conventional imaging. The objective of this study was to develop and evaluate machine learning approaches for differentiating peripheral schwannomas from neurofibromas. Methods We assembled a cohort of schwannomas and neurofibromas from 3 independent institutions and extracted high-dimensional radiomic features from gadolinium-enhanced, T1-weighted MRI using the PyRadiomics package on Quantitative Imaging Feature Pipeline. Age, sex, neurogenetic syndrome, spontaneous pain, and motor deficit were recorded. We evaluated the performance of 6 radiomics-based classifier models with and without clinical features and compared model performance against human expert evaluators. Results One hundred and seven schwannomas and 59 neurofibromas were included. The primary models included both clinical and imaging data. The accuracy of the human evaluators (0.765) did not significantly exceed the no-information rate (NIR), whereas the Support Vector Machine (0.929), Logistic Regression (0.929), and Random Forest (0.905) classifiers exceeded the NIR. Using the method of DeLong, the AUCs for the Logistic Regression (AUC = 0.923) and K Nearest Neighbor (AUC = 0.923) classifiers were significantly greater than the human evaluators (AUC = 0.766; p = 0.041). Conclusions The radiomics-based classifiers developed here proved to be more accurate and had a higher AUC on the ROC curve than expert human evaluators. This demonstrates that radiomics using routine MRI sequences and clinical features can aid in differentiation of peripheral schwannomas and neurofibromas.
In vitro Characterization of Mesenchymal Stem Cell Biology on Biomimetic Poly-ε-caprolactone Nanofiber Scaffolding
Ramesh, Gautam , Franchi, Federico , Jana, Soumen , Rodriguez‐Porcel, Martin

Mayo Clinic

No container title available | September 6, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14293/s2199-1006.1.sor-.ppc6rx2.v1 Get It

Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma
Paz‐Fumagalli, Ricardo , Core, Jacob , Padula, Carlos A. , Montazeri, Seyed Ali , McKinney, J. Mark , Frey, Gregory, Devcic, Zlatko , Lewis, Andrew R. , Ritchie, Charles , Mody, Kabir , Toskich, Beau , Padula, Carlos, Montazeri, Seyed, McKinney, John, Lewis, Andrew , Montazeri, S Ali , Frey, G. , Krishnan, Sunil

Mayo Clinic

Oncotarget | September 6, 2021 | Volume: 12 | Issue: 20 | Pages: 2075-2088

10.18632/oncotarget.28060 | PMID 34611481 Get It

Genetics and Antiepileptic Mood Stabilizer Treatment Response in Bipolar Disorder: What do we Know?
Ho, Ada Man‐Choi , Weinshilboum, Richard M. , Frye, Mark A. , Biernacka, Joanna M. , Ho, Ada M-C , Biernacka, Joanna , Weinshilboum, Richard M.

Mayo Clinic

Pharmacogenomics | September 6, 2021 | Volume: 22 | Issue: 14 | Pages: 913-925

10.2217/pgs-2021-0041 | PMID 34486896 Get It

Progression of PTH Resistance in Autosomal Dominant Pseudohypoparathyroidism Type Ib Due to Maternal STX16 Deletions
Kiuchi, Zentaro , Reyes, Monica, Hanna, Patrick , Sharma, Anu , DeClue, Terry J., Olney, Robert C. , Tebben, Peter J. , Jüppner, Harald , Tebben, Peter, Tebben, Peter

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 6, 2021 | Volume: 107 | Issue: 2 | Pages: e681-e687

10.1210/clinem/dgab660 | PMID 34477200 Get It

Abstract Context Maternally inherited STX16 deletions that cause loss of methylation at GNAS exon A/B and thereby reduce Gsα expression are the most frequent cause of autosomal dominant pseudohypoparathyroidism type Ib (AD-PHP1B). Early identification of these disease-causing variants in the children of affected and unaffected female carriers would prompt treatment with calcium and calcitriol once parathyroid hormone (PTH) levels increase, thereby preventing hypocalcemia and associated complications. Objective This study aimed to determine when PTH and calcium abnormalities develop after birth if a STX16 deletion is inherited maternally. Methods Forty-four children of affected (n = 7) or unaffected (n = 7) females with a STX16 deletion were investigated for the presence of these variants. If a deletion was identified, measurement of PTH, calcium, phosphate, and thyrotropin (TSH) was advised. Results The STX16 deletion that causes AD-PHP1B was identified in 25 children. Pretreatment laboratory results were available for 19 of those cases. Elevated PTH levels were detected by 2 years of age, and these were progressively higher if laboratory testing was first performed after establishing the genetic defect later in life. Total serum calcium levels remained within normal limits until about 5 years of age. TSH levels showed no consistent rise over time. Conclusion Establishing whether a STX16 deletion is inherited from a female carrier of a disease-causing variant rapidly establishes the diagnosis of AD-PHP1B. Several years before overt hypocalcemia developed, PTH levels increased, thereby establishing the onset of PTH resistance. Our findings provide diagnostic guidance and when treatment with calcium and calcitriol should be considered in order to prevent hypocalcemia and associated sequelae.
Incidence, risk factors, natural history and outcomes of heart failure in patients with Graves’ disease
Naser, Jwan A. , Stan, Marius N. , Lin, Grace , Pislaru, Sorin, Stan, Marius N , Naser, Jwan A , Pislaru, Sorin V.

Mayo Clinic

Heart | September 6, 2021 | Volume: 108 | Issue: 11 | Pages: 868-874

10.1136/heartjnl-2021-319752 | PMID 34489313 Get It

Objective Graves’ disease (GD) can both aggravate pre-existing cardiac disease and cause de novo heart failure (HF), but large-scale studies are lacking. We aimed to investigate the incidence, risk factors and outcomes of incident GD-related HF. Methods Patients with GD (2009–2019) were retrospectively included. HF with reduced ejection fraction (HFrEF) was defined by left ventricular ejection fraction <50% and Framingham criteria, while HF with preserved ejection fraction (HFpEF) was defined according to the HFA-PEFF criteria. HF due to ischaemia, valve disorder or other structural heart disease was excluded. Proportional hazards regression was used to analyse risk factors and outcomes. Results Of 1371 patients with GD, HF occurred in 74 (5.4%) patients (31 (2.3%) HFrEF; 43 (3.1%) HFpEF). In HFrEF, atrial fibrillation (AF) (HR 10.5 (3.0–37.3), p<0.001) and thyrotropin receptor antibody (TRAb) level (HR 1.05 (1.01–1.09) per unit, p=0.007) were independent risk factors. In HFpEF, the independent risk factors were chronic obstructive pulmonary disease (HR 7.2 (3.5–14.6), p<0.001), older age (HR 1.5 (1.2–2.0) per 10 years, p=0.001), overt hyperthyroidism (HR 6.4 (1.5–27.1), p=0.01), higher body mass index (BMI) (HR 1.07 (1.03–1.10) per unit, p=0.001) and hypertension (HR 3.1 (1.3–7.2), p=0.008). The risk of cardiovascular hospitalisations was higher in both HFrEF (HR 10.3 (5.5–19.4), p<0.001) and HFpEF (HR 6.7 (3.7–12.2), p<0.001). However, only HFrEF was associated with an increased risk of all-cause mortality (HR 5.17 (1.3–19.9), p=0.02) and ventricular tachycardia/fibrillation (HR 64.3 (15.9–259.7), p<0.001). Conclusion De novo HF occurs in 5.4% of patients with GD and is associated with increased risk of cardiovascular hospitalisations and mortality. Risk factors include AF, higher TRAb, higher BMI and overt hyperthyroidism.
Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer
Oo, Htoo Zarni , Lohinai, Zoltán , Khazamipour, Nastaran, Lo, Joey, Kumar, Gunjan , Pihl, Jessica , Adomat, Hans , Nabavi, Noushin , Behmanesh, Hakhamanesh , Dagil, Robert , Choudhary, Swati , Gustavsson, Tobias , Clausen, Thomas Mandel , Esko, Jeffrey D. , Allen, Jeffrey W. , Tran, Nhan L. , Moldvay, Judit , Döme, Balázs , Salanti, Ali , Al-Nakouzi, Nader , Weiss, Glen J. , Daugaard, Mads , Dagil, Robert , Weiss, Glen J , Daugaard, Mads , Tran, Nhan L , Zhai, Beibei , Thompson, Michael A.

Mayo Clinic

Cancers | September 6, 2021 | Volume: 13 | Issue: 17 | Pages: 4489

10.3390/cancers13174489 | PMID 34503301 Get It

Broad-spectrum therapeutics in non-small cell lung cancer (NSCLC) are in demand. Most human solid tumors express proteoglycans modified with distinct oncofetal chondroitin sulfate (CS) chains that can be detected and targeted with recombinant VAR2CSA (rVAR2) proteins and rVAR2-derived therapeutics. Here, we investigated expression and targetability of oncofetal CS expression in human NSCLC. High oncofetal CS expression is associated with shorter disease-free survival and poor overall survival of clinically annotated stage I and II NSCLC patients (n = 493). Oncofetal CS qualifies as an independent prognosticator of NSCLC in males and smokers, and high oncofetal CS levels are more prevalent in EGFR/KRAS wild-type cases, as compared to mutation cases. NSCLC cell lines express oncofetal CS-modified proteoglycans that can be specifically detected and targeted by rVAR2 proteins in a CSA-dependent manner. Importantly, a novel VAR2-drug conjugate (VDC-MMAE) efficiently eliminates NSCLC cells in vitro and in vivo. In summary, oncofetal CS is a prognostic biomarker and an actionable glycosaminoglycan target in NSCLC.
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Bergholtz, Helga , Carter, Jodi M. , Cesano, Alessandra, Cheang, Maggie C.U. , Church, S. , Divakar, Prajan , Fuhrman, Christopher A. , Goel, Shom , Gong, Jingjing , Guerriero, Jennifer L. , Hoang, Margaret L. , Hwang, E. Shelley , Kuasne, Hellen, Lee, Jinho , Liang, Yan , Perez, Jessica, Prat, Aleix , Pusztai, Lajos , Reeves, Jason , Riazalhosseini, Yasser , Richer, Jennifer K. , Şahin, Özgür , Sato, Hiromi , Sørlie, Thérese , Swarbrick, Alexander , Thompson, E. Aubrey , Tolaney, Sara M. , Warren, Sarah H. , Cheang, Maggie Chon U , Church, Sarah E , Prat, Aleix , Pusztai, Lajos , Sahin, Özgür , Sørlie, Therese , Liang, Yan , Carter, Jodi , Mittendorf, EA , Schlam, Ilana Miriam , Stover, Daniel G. , Swain, Sandra M. , Warren, Sarah

Mayo Clinic

Cancers | September 6, 2021 | Volume: 13 | Issue: 17 | Pages: 4456

10.3390/cancers13174456 | PMID 34503266 Get It

Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication. High-plex spatial profiling of tumors enables characterization of heterogeneity in the breast TME, which can holistically illuminate the biology of tumor growth, dissemination and, ultimately, response to therapy. The GeoMx Digital Spatial Profiler (DSP) enables researchers to spatially resolve and quantify proteins and RNA transcripts from tissue sections. The platform is compatible with both formalin-fixed paraffin-embedded and frozen tissues. RNA profiling was developed at the whole transcriptome level for human and mouse samples and protein profiling of 100-plex for human samples. Tissue can be optically segmented for analysis of regions of interest or cell populations to study biology-directed tissue characterization. The GeoMx Breast Cancer Consortium (GBCC) is composed of breast cancer researchers who are developing innovative approaches for spatial profiling to accelerate biomarker discovery. Here, the GBCC presents best practices for GeoMx profiling to promote the collection of high-quality data, optimization of data analysis and integration of datasets to advance collaboration and meta-analyses. Although the capabilities of the platform are presented in the context of breast cancer research, they can be generalized to a variety of other tumor types that are characterized by high heterogeneity.
Rethinking Fragility Fractures in Type 2 Diabetes: The Link between Hyperinsulinaemia and Osteofragilitas
Cooper, Isabella D. , Brookler, Kenneth H. , Crofts, Catherine , Crofts, Catherine A P

Mayo Clinic

Biomedicines | September 6, 2021 | Volume: 9 | Issue: 9 | Pages: 1165

10.3390/biomedicines9091165 | PMID 34572351 Get It

Patients with type 2 diabetes mellitus (T2DM) and/or cardiovascular disease (CVD), conditions of hyperinsulinaemia, have lower levels of osteocalcin and bone remodelling, and increased rates of fragility fractures. Unlike osteoporosis with lower bone mineral density (BMD), T2DM bone fragility “hyperinsulinaemia-osteofragilitas” phenotype presents with normal to increased BMD. Hyperinsulinaemia and insulin resistance positively associate with increased BMD and fragility fractures. Hyperinsulinaemia enforces glucose fuelling, which decreases NAD+-dependent antioxidant activity. This increases reactive oxygen species and mitochondrial fission, and decreases oxidative phosphorylation high-energy production capacity, required for osteoblasto/cytogenesis. Osteocytes directly mineralise and resorb bone, and inhibit mineralisation of their lacunocanalicular space via pyrophosphate. Hyperinsulinaemia decreases vitamin D availability via adipocyte sequestration, reducing dendrite connectivity, and compromising osteocyte viability. Decreased bone remodelling and micropetrosis ensues. Trapped/entombed magnesium within micropetrosis fossilisation spaces propagates magnesium deficiency (MgD), potentiating hyperinsulinaemia and decreases vitamin D transport. Vitamin D deficiency reduces osteocalcin synthesis and favours osteocyte apoptosis. Carbohydrate restriction/fasting/ketosis increases beta-oxidation, ketolysis, NAD+-dependent antioxidant activity, osteocyte viability and osteocalcin, and decreases excess insulin exposure. Osteocalcin is required for hydroxyapatite alignment, conferring bone structural integrity, decreasing fracture risk and improving metabolic/endocrine homeodynamics. Patients presenting with fracture and normal BMD should be investigated for T2DM and hyperinsulinaemia.
Mitochondrially localized MPZL3 emerges as a signaling hub of mammalian physiology
Wikramanayake, Tongyu C. , Nicu, Carina , Chéret, Jérémy , Paus, Ralf , Czyzyk, Traci A , Paus, Ralf , Czyzyk, Traci A.

Mayo Clinic

BioEssays | September 6, 2021 | Volume: 43 | Issue: 10 | Pages: No page available

10.1002/bies.202100126 | PMID 34486148 Get It

AbstractMPZL3 is a nuclear‐encoded, mitochondrially localized, immunoglobulin‐like V‐type protein that functions as a key regulator of epithelial cell differentiation, lipid metabolism, ROS production, glycemic control, and energy expenditure. Recently, MPZL3 has surfaced as an important modulator of sebaceous gland function and of hair follicle cycling, an organ transformation process that is also governed by peripheral clock gene activity and PPARγ. Given the phenotype similarities and differences between Mpzl3 and Pparγ knockout mice, we propose that MPZL3 serves as a signaling hub that is regulated by core clock gene products and/or PPARγ to translate signals from these nuclear transcription factors to the mitochondria to modulate circadian and metabolic regulation. Conservation between murine and human MPZL3 suggests that human MPZL3 may have similarly complex functions in health and disease. We summarize current knowledge and discuss future directions to elucidate the full spectrum of MPZL3 functions in mammalian physiology.